GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmena SA (WAR:PHR) » Definitions » EV-to-FCF

Pharmena (WAR:PHR) EV-to-FCF : 1.55 (As of Jun. 04, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Pharmena EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmena's Enterprise Value is zł46.67 Mil. Pharmena's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was zł30.10 Mil. Therefore, Pharmena's EV-to-FCF for today is 1.55.

The historical rank and industry rank for Pharmena's EV-to-FCF or its related term are showing as below:

WAR:PHR' s EV-to-FCF Range Over the Past 10 Years
Min: -923.57   Med: -21.55   Max: 837.99
Current: 1.51

During the past 13 years, the highest EV-to-FCF of Pharmena was 837.99. The lowest was -923.57. And the median was -21.55.

WAR:PHR's EV-to-FCF is ranked better than
61.11% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs WAR:PHR: 1.51

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Pharmena's stock price is zł6.04. Pharmena's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was zł2.630. Therefore, Pharmena's PE Ratio for today is 2.30.


Pharmena EV-to-FCF Historical Data

The historical data trend for Pharmena's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmena EV-to-FCF Chart

Pharmena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.34 -39.71 -24.60 38.28 1.73

Pharmena Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.00 0.96 1.30 1.73 2.39

Competitive Comparison of Pharmena's EV-to-FCF

For the Biotechnology subindustry, Pharmena's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmena's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmena's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmena's EV-to-FCF falls into.



Pharmena EV-to-FCF Calculation

Pharmena's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=46.667/30.103
=1.55

Pharmena's current Enterprise Value is zł46.67 Mil.
Pharmena's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł30.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmena  (WAR:PHR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharmena's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.04/2.630
=2.30

Pharmena's share price for today is zł6.04.
Pharmena's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.630.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharmena EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharmena's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmena (WAR:PHR) Business Description

Traded in Other Exchanges
N/A
Address
Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.